Dual CAR-T cell therapy - Poseida Therapeutics/Roche
Alternative Names: TSCM-rich dual CAR-T cell therapy - Poseida Therapeutics/RocheLatest Information Update: 03 Feb 2025
Price :
$50 *
At a glance
- Originator Poseida Therapeutics
- Developer Poseida Therapeutics; Roche
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haematological malignancies; Multiple myeloma